Labastida-Ramírez, Alejandro
Caronna, Edoardo
Gollion, Cédric
Stanyer, Emily
Dapkute, Austeja
Braniste, Diana
Naghshineh, Hoda
Meksa, Liga
Chkhitunidze, Nino
Gudadze, Tamari
Pozo-Rosich, Patricia
Burstein, Rami
Hoffmann, Jan
Article History
Received: 2 June 2023
Accepted: 1 August 2023
First Online: 11 September 2023
Declarations
:
: Not applicable.
: Not applicable.
: ALR, CG, ES, AD, DB, HN, LM, NC, and TG do not report a conflict of interest. EC has received honoraria from Novartis, Chiesi, Lundbeck, Medscape. PPR has received honoraria as a consultant and speaker, in the last three years, for: AbbVie, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; and, has received funding for clinical trials from Alder, AbbVie, Amgen, Biohaven, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva. She is the Honorary Secretary of the International Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology. She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder ofExternalRef removed. Pozo-Rosich P does not own stocks from any pharmaceutical company. RB is the John Hedley-Whyte Professor of Anesthesia and Neuroscience at the Beth Israel Deaconess Medical Center and Harvard Medical School. He has received research support from the NIH: R01 NS094198-01A1, R37 NS079678, R01NS095655, R01 NS104296, R21 NS106345, Allergan, Teva, Dr. Reddy, Eli Lilly, Trigemina and the Migraine Research Foundation. He is a reviewer for NINDS, holds stock options in AllayLampand Percept; serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, CGRP Diagnostic, Dr. Reddy’s Laboratory, ElectroCore, Eli Lilly, GlaxoSmithKline, Merck, Pernix, Theranica, Teva, and Trigemina. CME fees from Healthlogix, Medlogix, WebMD/Medscape, and Patents 9061025, 11732265.1, 10806890, US2021-0015908, WO21007165, US2021-0128724, WO21005497. JH received honoraria for consulting activities and/or serving on advisory boards and/or as a speaker from Allergan, Abbvie, Autonomic Technologies Inc., Cannovex BV, Chordate Medical AB, Eli Lilly, Hormosan Pharma, Lundbeck, MD-Horizonte, Novartis, Sanofi and Teva. He received personal fees for Medico-Legal work as well as from NEJM Journal Watch, Oxford University Press, Quintessence Publishing, Sage Publishing and Springer Healthcare. He holds stock options from Chordate Medical AB. He also reports a research grant from Bristol Myers Squibb. Jan Hoffmann serves as Associate Editor for Cephalalgia, Cephalalgia Reports, Journal of Headache and Facial Pain, Journal of Oral & Facial Pain and Headache as well as for Frontiers in Pain Research. He is an elected member of the Board of Trustees as well as the Science and Research Committee of the International Headache Society (IHS) and serves as a Council Member and Treasurer of the British Association for the Study of Headache (BASH). The article-processing charges for the article has been kindly sponsored by the European Headache Federation.